Key Findings
Preclinical research published in Biomarker Research demonstrates that engineered natural killer (NK) cells targeting the CD73 molecule can eliminate hard-to-treat lung adenocarcinoma. In laboratory assays, CD73-CAR-NK-92 cells achieved near-complete destruction of CD73-high PC-9 and H1299 cells, whereas parental NK-92 cells managed only roughly 50% to 60% killing. The engineered cells also showed minimal toxicity toward BEAS-2B cells, with killing remaining below 20% across all tested effector-to-target ratios.
Technical Details
The researchers developed a second-generation chimeric antigen receptor (CAR) consisting of an anti-CD73 single-chain variable fragment, a 4-1BB costimulatory domain, and a CD3ζ signaling module. This construct was introduced into NK-92 cells via lentiviral delivery, achieving approximately 50% transduction efficiency before selection. Bulk RNA sequencing revealed that engineered cells upregulated cytotoxicity genes such as FASLG, GZMA, and GZMB, while inhibitory receptors including KLRC1, KLRD1, and HAVCR2 were downregulated.
Functional assays showed that CD73-CAR-NK-92 cells released higher levels of perforin, granzyme B, TNF-α, and IFN-γ when co-cultured with H1299 cells. Furthermore, the CAR-NK cells resisted the suppressive effects of exogenous adenosine (10 micromolar), which typically impairs parental NK-92 cytotoxicity by triggering A2AR-cAMP-PKA signaling.
Background & Context
CD73, encoded by the NT5E gene, is an enzyme that produces extracellular adenosine, which dampens T cell and NK cell activity. It also promotes metastatic spread and epithelial-to-mesenchymal transition. Non-small cell lung cancer exhibits high CD73 expression, often amplified by mutant EGFR and KRAS. Data from the TCGA lung adenocarcinoma cohort and immunohistochemical analysis indicated that CD73 protein and NT5E mRNA expression are higher in relapsed or refractory specimens compared to primary tumors.
Significance & Outlook
This proof-of-concept strategy provides a dual-action attack: it destroys cells displaying CD73 and eliminates the “adenosine factory” that protects tumors from the immune system. While antibodies and small molecules targeting CD73 are in clinical testing, they lack direct tumor-killing capacity. This CAR-NK approach addresses both the enzymatic and non-enzymatic contributions of CD73 to tumor progression.
Source: https://bioengineer.org/engineered-nk-cells-target-cd73-to-attack-hard-to-treat-lung-adenocarcinoma/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
